Change in fibrosis score as a predictor of mortality among HIV-infected patients with viral hepatitis

AIDS Patient Care and STDs

Volumn 26, Issue 2, 2012, Pages 73-80

  Jain, Mamta K ^a   Seremba, Emmanuel ^a   Bhore, Rafia ^b   Dao, Doan ^a   Joshi, Reeti ^a   Attar, Nahid ^a   Yuan, He Jun ^a   Lee, William M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; PREDICTOR VARIABLE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SURVIVAL; VIRUS HEPATITIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; COHORT STUDIES; COINFECTION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS C; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84863033935     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2011.0191     Document Type: Article

References (30)

1. Germani G, Burroughs AK, Dhillon AP. The relationship between liver disease stage and liver fibrosis: A tangled web. Histopathology 2010;57:773-784.
2. Patel K, Benhamou Y, Yoshida EM, et al. An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. J Viral Hepat 2009;16:178-186.
3. Smith JO, Sterling RK. Systematic review: Non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther 2009;30:557-576.
4. Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: A systematic review of diagnostic test accuracy. Am J Gastroenterol 2007;102:2589-2600. (Pubitemid 47631778)
5. Morra R, Munteanu M, Imbert-Bismut F, Messous D, Ratziu V, Poynard T. FibroMAX: Towards a new universal biomarker of liver disease? Expert Rev Mol Diagn 2007;7:481-490. (Pubitemid 47547715)
6. Loko MA, Castera L, Dabis F, et al. Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 Aquitaine cohort. Am J Gastroenterol 2008;103:1973-1980.
7. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38: 518-526. (Pubitemid 36919874)
8. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43: 1317-1325. (Pubitemid 43980111)
9. Macias J, Giron-Gonzalez JA, Gonzalez-Serrano M, et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut 2006;55:409-414. (Pubitemid 43268282)
10. Nunes D, Fleming C, Offner G, et al. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol 2010;105:1346-1353.
11. Cacoub P, Carrat F, Bedossa P, et al. Comparison of noninvasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study-ANRS HC02. J Hepatol 2008; 48:765-773.
12. Mallet V, Dhalluin-Venier V, Roussin C, et al. The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B. Aliment Pharmacol Ther 2009;29:409-415.
13. Shin WG, Park SH, Jang MK, et al. Aspartate aminotransferase to platelet ratio index (APRI) can predict liver fibrosis in chronic hepatitis B. Dig Liver Dis 2008;40:267-274. (Pubitemid 351292341)
14. Trang T, Petersen JR, Snyder N. Non-invasive markers of hepatic fibrosis in patients co-infected with HCV and HIV: comparison of the APRI and FIB-4 index. Clin Chim Acta 2008;397:51-54.
15. Wai CT, Cheng CL, Wee A, et al. Non-invasive models for predicting histology in patients with chronic hepatitis B. Liver Int 2006;26:666-672. (Pubitemid 43983883)
16. Xiong Z. %YAMGAST: Yet another macro to generate a summary table. In: Pharmaceutical Industry SAS Users Group (PharmaSUG) Proceedings; 2008: P004.
17. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864-871. (Pubitemid 30169932)
18. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology 2007;45:797-805. (Pubitemid 46450631)
19. Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: A cohort study. AIDS 2004;18:2039-2045. (Pubitemid 39463357)
20. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007;146:87-95. (Pubitemid 351640011)
21. Achhra AC, Amin J, Law MG, et al. Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS 2010; 24:1877-1886.
22. Chuang CS, Tung SY, Lee IL, et al. Clinical features and outcome of chronic viral hepatitis with acute exacerbation in patients with concurrent infections of hepatitis B and C virus. Dig Dis Sci 2008;53:511-516.
23. Sagnelli E, Coppola N, Marrocco C, et al. Hepatitis C virus superinfection in hepatitis B virus chronic carriers: A reciprocal viral interaction and a variable clinical course. J Clin Virol 2006;35:317-320. (Pubitemid 43188980)
24. Morsica G, Bagaglio S, Cicconi P, et al. Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients. J Acquir Immune Defic Syndr 2009;51:574-581.
25. Chen LS, Yen MF, Wu HM, et al. Predictive survival model with time-dependent prognostic factors: Development of computer-aided SAS Macro program. J Eval Clin Pract 2005;11:181-193.
26. Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009;50:407-413.
27. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677-684. (Pubitemid 351664462)
28. Camma C, Di Bona D, Schepis F, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: A meta-analysis of individual patient data. Hepatology 2004;39:333-342. (Pubitemid 38222174)
29. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122: 1303-1313. (Pubitemid 34465173)
30. Halfon P, Carrat F, Bedossa P, et al. Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: The Fibrovic 2 Study - ANRS HC02. Antivir Ther 2009;14:211-219.